Guidelines for the acute coronary syndromes
1Cardiology Division, San Francisco General Hospital, University of California San Francisco, 1001 Portrero Avenue, San Francisco, CA 94110, USA. erapapor@sfghdean.ucsf.edu
Insights
Acute coronary syndrome management has improved, with enoxaparin and glycoprotein IIb/IIIa inhibitors showing benefits. Aggressive treatment strategies are recommended for high-risk patients for better outcomes.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Established acute coronary syndrome (ACS) management strategies significantly reduce early mortality and myocardial infarction.
- Enoxaparin offers incremental benefits over unfractionated heparin in ACS treatment.
- Glycoprotein IIb/IIIa inhibitors are beneficial during percutaneous coronary intervention for ACS.
Framework:
- Evaluating the efficacy of glycoprotein IIb/IIIa inhibitors in medical management alone for ACS.
- Assessing the comparative effectiveness of aggressive versus conservative treatment approaches in high-risk ACS patients.
Implementation:
- The use of enoxaparin as a preferred anticoagulant in ACS.
- Strategic administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
- Implementing aggressive management protocols for high-risk ACS individuals.
Implications:
- Glycoprotein IIb/IIIa inhibitors' benefit is questionable in non-interventional ACS management.
- Aggressive treatment paradigms show promise for improved long-term outcomes in high-risk ACS patients.
- Optimizing ACS treatment pathways requires careful consideration of intervention versus medical management.
Abstract:
Traditional measures employed in the immediate management of patients presenting with an acute coronary syndrome have markedly reduced the risk of early death or myocardial infarction. Further incremental benefit is seen with the substitution of enoxaparin for unfractionated heparin, and in the use of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. However, the evidence for benefit from the glycoprotwin IIb/IIIa inhibitors with medical management alone is unconvincing. Newer data also suggest an aggressive approach to the high-risk patient offers a better ultimate outcome than a conservative one.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management
Introduction Cardiac Emergencies


